US5236904A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Erection-inducing methods and compositions
Assignee: Senetek PLC
•
Filing: 1989-09-18
•
Granted: 1993-08-17
•
Expires: 2009-09-18
Abstract
Abstract The present invention provides methods and compositions for inducing penile erections, sufficient for vaginal penetration, in a human male suffering from impotence. When the impotence is substantially only neurogenic, psycogenic or neurogenic and psychogenic, a method of the invention comprises (A) administering to the male by intracavernosal injection peptide N-terminal histidine C-terminal methionineamide and (B) sexually stimulating the male. When the impotence is caused by severe atherosclerosis, a method of the invention comprises (A) administering to the male by intracavernosal injection an amount of a physiologically acceptable composition comprising (1) a neuropeptide selected from the group consisting of human vasoactive intestinal peptide and peptide N-terminal histidine C-terminal methionineamide and (2) an alpha-adrenergic blocker, such as phentolamine or prazosin, and (B) sexually stimulating the male. The invention also entails a physiologically acceptable composition suitable for use in inducing, upon administration by intracavernosal injection, an erection, sufficient for vaginal penetration, in a human male suffering from impotence, which is caused by severe atherosclerosis, which composition comprises (1) a neuropeptide selected from the group consisting of vasoactive intestinal peptide and peptide N-terminal histidine C-terminal methionineamide and (2) an alpha-adrenergic blocker, such as phentolamine or prazosin.
Inventors
- 👤 Thomas Gerstenberg
- 👤 Jan Fahrenkrug
- 👤 Bent Ottesen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 11:34
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/2278; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/4164; A61K31/417; A61K31/495; A61K31/505; A61K31/517; A61K9/00; A61K9/0012; A61K9/0019; A61P; A61P13/00; A61P13/02; A61P15/00; A61P15/10; A61K9/0034
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
89 words
A method of inducing an erection in a human male suffering from impotence, comprising: (A) administering to said male by intracavernosal injection an erection-inducing-effective amount of peptide histidine methionine (PHM) or vasoactive intestinal peptide (VIP) in a physiologically acceptable solution; and (B) sexually stimulating said male, wherein: the amount of PHM or VIP is effective in the absence of any other erection-inducing compounds to induce an erection sufficient for vaginal penetration in the presence of sexual stimulation in said male; and said impotence is substantially neurogenic or psychogenic impotence.
Claim 2
Independent Claim
89 words
A method of inducing an erection in a human male suffering from impotence, comprising: (A) administering to said male by intracavernosal injection an erection-inducing-effective amount of peptide histidine methionine (PHM) or vasoactive intestinal peptide (VIP) in a physiologically acceptable solution; and (B) sexually stimulating said male, wherein: the amount of PHM or VIP is effective in the absence of any other erection-inducing compounds to induce an erection sufficient for vaginal penetration in the presence of sexual stimulation in said male; and said impotence is substantially neurogenic or psychogenic impotence.
Claim 3
Dependent Claim
37 words
The method of claim 1, wherein the volume of the physiologically acceptable solution administered to the male is between 0.1 ml and 5 ml and the amount of PHM administered is between 10 μg and 60 μg.
Claim 4
Independent Claim
81 words
A method of inducing an erection sufficient for vaginal penetration in a human male suffering from impotence, comprising: (A) administering to said male by intracavernosal injection a physiologically acceptable composition containing (i) between 15 μg and 60 μg of a neuropeptide selected from the group consisting of vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) and (ii) an alpha-adrenergic blocker, at a dose effective to induce such an erection when administered with said neuropeptide; and (B) sexually stimulating said male.
Claim 5
Independent Claim
81 words
A method of inducing an erection sufficient for vaginal penetration in a human male suffering from impotence, comprising: (A) administering to said male by intracavernosal injection a physiologically acceptable composition containing (i) between 15 μg and 60 μg of a neuropeptide selected from the group consisting of vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) and (ii) an alpha-adrenergic blocker, at a dose effective to induce such an erection when administered with said neuropeptide; and (B) sexually stimulating said male.
Claim 6
Dependent Claim
10 words
The method of claim 3, wherein said neuropeptide is VIP.
Claim 7
Dependent Claim
10 words
The method of claim 3, wherein said neuropeptide is PHM.
Claim 8
Dependent Claim
56 words
The method of claim 4, wherein the volume of said injected, physiologically acceptable composition is between 0.1 ml and 5 ml, inclusive, and said alpha-adrenergic blocker is selected from the group consisting of phentolamine, at a dose between 0.1 mg and 5 mg, inclusive, and prazosin, at a dose between 0.01 mg and 1 mg, inclusive.
Claim 9
Dependent Claim
56 words
The method of claim 5, wherein the volume of said injected, physiologically acceptable composition is between 0.1 ml and 5 ml, inclusive, and said alpha-adrenergic blocker is selected from the group consisting of phentolamine, at a dose between 0.1 mg and 5 mg, inclusive, and prazosin, at a dose between 0.01 mg and 1 mg, inclusive.
Claim 10
Dependent Claim
11 words
The method of claim 6, wherein said alpha-adrenergic blocker is phentolamine.
Claim 11
Dependent Claim
11 words
The method of claim 7, wherein said alpha-adrenergic blocker is phentolamine.
Claim 12
Independent Claim
42 words
A method according to any one of claims 1-9 wherein, for between 1 minute and 10 minutes after the injection, the penis of the male is constricted between the base thereof and the point on the penis at which the injection occurred.
Claim 13
Dependent Claim
28 words
A method according to claim 10 wherein the sexual stimulation of the male is sexual stimulation in the course of sexual relations between said male and another person.
Claim 14
Dependent Claim
22 words
A method according to claim 10 wherein the sexual stimulation of the male is by penile vibration simultaneously with visual sexual stimulation.
Claim 15
Dependent Claim
114 words
A composition formulated as a single dose that is physiologically acceptable for administration to a human male by intracavernosal injection, comprising: (i) a neuropeptide selected from the group consisting of vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM), and (ii) an alpha-adrenergic blocker, wherein: the amounts of said neuropeptide and blocker are, with sexual stimulation, effective, in the absence of other erection-inducing substances to induce an erection when administered together by intracavernosal injection to a human male suffering from impotence: administration of a single dose of the composition does not cause priapism in a male treated therewith; the impotence is caused by severe atherosclerosis; and the induced erection is sufficient for vaginal penetration.
Claim 16
Dependent Claim
114 words
A composition formulated as a single dose that is physiologically acceptable for administration to a human male by intracavernosal injection, comprising: (i) a neuropeptide selected from the group consisting of vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM), and (ii) an alpha-adrenergic blocker, wherein: the amounts of said neuropeptide and blocker are, with sexual stimulation, effective, in the absence of other erection-inducing substances to induce an erection when administered together by intracavernosal injection to a human male suffering from impotence: administration of a single dose of the composition does not cause priapism in a male treated therewith; the impotence is caused by severe atherosclerosis; and the induced erection is sufficient for vaginal penetration.
Claim 17
Dependent Claim
18 words
The composition of claim 13, wherein the amount of the neuropeptide is between 15 μg and 60 μg.
Claim 18
Dependent Claim
10 words
The composition of claim 14, wherein the neuropeptide is VIP.
Claim 19
Dependent Claim
11 words
A composition according to claim 14 wherein the neuropeptide is PHM.
Claim 20
Dependent Claim
39 words
The composition of claim 15, wherein said alpha-adrenergic blocker is selected from the group consisting of phentolamine, at a concentration of between 2 μg/ml and 20 mg/ml and prazosin, at a concentration of between 2 μg/ml and 10 mg/ml.
Claim 21
Dependent Claim
39 words
The composition of claim 16, wherein said alpha-adrenergic blocker is selected from the group consisting of phentolamine, at a concentration of between 2 μg/ml and 20 mg/ml and prazosin, at a concentration of between 2 μg/ml and 10 mg/ml.
Claim 22
Dependent Claim
12 words
A composition according to claim 17 wherein said alpha-adrenergic blocker is phentolamine.
Claim 23
Dependent Claim
12 words
A composition according to claim 18 wherein said alpha-adrenergic blocker is phentolamine.
Claim 24
Dependent Claim
43 words
A composition that is physiologically acceptable for administration to a human male by intracavernosal injection, consisting essentially of: (a) 5-500 μg/ml of vasoactive intestinal peptide (VIP) peptide or histidine methionine (PHM); and (b) 20 μg/ml-20 mg/ml of phentolamine in a physiologically acceptable solution.
Claim 25
Dependent Claim
43 words
A composition that is physiologically acceptable for administration to a human male by intracavernosal injection, consisting essentially of: (a) 5-500 μg/ml of vasoactive intestinal peptide (VIP) peptide or histidine methionine (PHM); and (b) 20 μg/ml-20 mg/ml of phentolamine in a physiologically acceptable solution.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-08-16 | 1997-02-15 | 1997-08-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-08-16 | 2001-02-15 | 2001-08-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-08-16 | 2005-02-15 | 2005-08-17 | $7700.00 | Window Closed / Lapsed |